-
1
-
-
0038460302
-
The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report
-
May 21;
-
Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003 May 21; 289 (19): 2560-72
-
(2003)
JAMA
, Issue.19
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
-
2
-
-
49449084783
-
-
Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article. Cirulation 2005 Sep 20; 112 (12): 1888-916
-
Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article. Cirulation 2005 Sep 20; 112 (12): 1888-916
-
-
-
-
3
-
-
33749152764
-
COMPARE: Comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure
-
Oct 2;
-
Greenberg BH, Mehra M, Teerlink JR, et al. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure. Am J Cardiol 2006 Oct 2; 98 Suppl. 1 (7): 53L-9L
-
(2006)
Am J Cardiol
, vol.98
, Issue.SUPPL. 1 7
-
-
Greenberg, B.H.1
Mehra, M.2
Teerlink, J.R.3
-
4
-
-
39049177405
-
-
Weber MA, Bakris GL, Tarka EA, et al. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension [published erratum appears in J Clin Hypertens 2007 Feb; 9 (2): 154]. J Clin Hypertens 2006 Dec; 8 (12): 840-9
-
Weber MA, Bakris GL, Tarka EA, et al. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension [published erratum appears in J Clin Hypertens 2007 Feb; 9 (2): 154]. J Clin Hypertens 2006 Dec; 8 (12): 840-9
-
-
-
-
5
-
-
33749118012
-
Rationale and design of CASPER: Compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure
-
Oct 2;
-
Hauptman PJ, Pressler SJ, Sackner-Bernstein J, et al. Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure. Am J Cardiol 2006 Oct 2; 98 (7 Suppl. 1): 60L-6L
-
(2006)
Am J Cardiol
, vol.98
, Issue.7 SUPPL. 1
-
-
Hauptman, P.J.1
Pressler, S.J.2
Sackner-Bernstein, J.3
-
6
-
-
49449113019
-
-
Coreg (carvedilol) tablets: US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2007
-
Coreg (carvedilol) tablets: US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2007
-
-
-
-
7
-
-
49449110338
-
-
GlaxoSmithKline. FDA approves new, once-a-day Coreg CR for the treatment of three key cardiovascular conditions [online]. Available from URL: http://www.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=918 [Accessed 2008 Jan 3]
-
GlaxoSmithKline. FDA approves new, once-a-day Coreg CR for the treatment of three key cardiovascular conditions [online]. Available from URL: http://www.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=918 [Accessed 2008 Jan 3]
-
-
-
-
8
-
-
49449105778
-
-
Coreg CR (carvedilol phosphate) extended-release capsules: US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2007 Oct
-
Coreg CR (carvedilol phosphate) extended-release capsules: US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2007 Oct
-
-
-
-
9
-
-
33749134422
-
Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension
-
Oct 2;
-
Henderson LS, Tenero DM, Baidoo CA, et al. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am J Cardiol 2006 Oct 2; 98 (7 Suppl. 1): 17L-26L
-
(2006)
Am J Cardiol
, vol.98
, Issue.7 SUPPL. 1
-
-
Henderson, L.S.1
Tenero, D.M.2
Baidoo, C.A.3
-
10
-
-
85047673757
-
Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients
-
Eggertsen R, Andren L, Sivertsson R, et al. Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients. Eur J Clin Pharmacol 1984; 27 (1): 19-22
-
(1984)
Eur J Clin Pharmacol
, vol.27
, Issue.1
, pp. 19-22
-
-
Eggertsen, R.1
Andren, L.2
Sivertsson, R.3
-
11
-
-
0025863481
-
Acute haemodynamic effects of carvedilol in essential hypertension at rest and during exercise
-
Sep;
-
Omvik P, Lund-Johansen P. Acute haemodynamic effects of carvedilol in essential hypertension at rest and during exercise. Eur Heart J 1991 Sep; 12 (6): 736-40
-
(1991)
Eur Heart J
, vol.12
, Issue.6
, pp. 736-740
-
-
Omvik, P.1
Lund-Johansen, P.2
-
12
-
-
0023638237
-
Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension
-
Dupont AG, Van der Niepen P, Taeymans Y, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S130-6
-
(1987)
J Cardiovasc Pharmacol
, vol.10
, Issue.SUPPL. 11
-
-
Dupont, A.G.1
Van der Niepen, P.2
Taeymans, Y.3
-
13
-
-
0026741197
-
Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects
-
Cournot A, Lim C, Duchier J, et al. Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects. J Cardiovasc Pharmacol 1992; 19 Supp. 1: S35-9
-
(1992)
J Cardiovasc Pharmacol
, vol.19
, Issue.SUPP. 1
-
-
Cournot, A.1
Lim, C.2
Duchier, J.3
-
14
-
-
0021746176
-
Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension
-
Oct;
-
Eggertsen R, Sivertsson R, Andren L, et al. Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension. J Hypertens 1984 Oct; 2 (5): 529-34
-
(1984)
J Hypertens
, vol.2
, Issue.5
, pp. 529-534
-
-
Eggertsen, R.1
Sivertsson, R.2
Andren, L.3
-
15
-
-
0023609539
-
Acute and long-term hemodynamic effects of carvedilol, a combined β-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients
-
Eggertsen R, Sivertsson R, Andrén L, et al. Acute and long-term hemodynamic effects of carvedilol, a combined β-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S97-S100
-
(1987)
J Cardiovasc Pharmacol
, vol.10
, Issue.SUPPL. 11
-
-
Eggertsen, R.1
Sivertsson, R.2
Andrén, L.3
-
16
-
-
0026573297
-
Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise
-
Feb;
-
Lund-Johansen P, Omvik P. Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise. Eur Heart J 1992 Feb; 13 (2): 281-6
-
(1992)
Eur Heart J
, vol.13
, Issue.2
, pp. 281-286
-
-
Lund-Johansen, P.1
Omvik, P.2
-
17
-
-
0035131087
-
Dilated cardiomyopathy in dialysis patients: Beneficial effects of carvedilol. A double-blind, placebo-controlled trial
-
Cice G, Ferrara L, Di Benedetto A, et al. Dilated cardiomyopathy in dialysis patients: beneficial effects of carvedilol. A double-blind, placebo-controlled trial. J Am Coll Cardiol 2001; 37 (2): 407-11
-
(2001)
J Am Coll Cardiol
, vol.37
, Issue.2
, pp. 407-411
-
-
Cice, G.1
Ferrara, L.2
Di Benedetto, A.3
-
18
-
-
0033230514
-
Beta-blockade in heart failure: A comparison of carvedilol with metoprolol
-
Sanderson JE, Chan S, Yip G, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999; 34 (5): 1522-8
-
(1999)
J Am Coll Cardiol
, vol.34
, Issue.5
, pp. 1522-1528
-
-
Sanderson, J.E.1
Chan, S.2
Yip, G.3
-
19
-
-
0032845314
-
Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvdilol
-
Sep;
-
Guazzi M, Agostoni P, Matturri M, et al. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvdilol. Am Heart J 1999 Sep; 138 (3): 460-7
-
(1999)
Am Heart J
, vol.138
, Issue.3
, pp. 460-467
-
-
Guazzi, M.1
Agostoni, P.2
Matturri, M.3
-
21
-
-
0026772962
-
Effect of carvedilol on left ventricular function and mass in hypertension
-
Why H, Richardson PJ. Effect of carvedilol on left ventricular function and mass in hypertension. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S50-4
-
(1992)
J Cardiovasc Pharmacol
, vol.19
, Issue.SUPPL. 1
-
-
Why, H.1
Richardson, P.J.2
-
22
-
-
0023624521
-
Resting and postexercise hemodynamic effects of carvedilol, a β-adrenergic blocker and precapillary vasodilator in hypertensive patients
-
Leonetti G, Sampieri L, Cuspidi C, et al. Resting and postexercise hemodynamic effects of carvedilol, a β-adrenergic blocker and precapillary vasodilator in hypertensive patients. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S94-6
-
(1987)
J Cardiovasc Pharmacol
, vol.10
, Issue.SUPPL. 11
-
-
Leonetti, G.1
Sampieri, L.2
Cuspidi, C.3
-
23
-
-
0031050642
-
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
-
Australia/New Zealand Heart Failure Research Collaborative Group, Feb 8;
-
Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997 Feb 8; 349 (9049): 375-80
-
(1997)
Lancet
, vol.349
, Issue.9049
, pp. 375-380
-
-
-
24
-
-
0029085811
-
Double-blind, placebo-controlled study of the long-term efficacy of carvdilol in patients with severe chronic heart failure
-
Sep 15;
-
Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvdilol in patients with severe chronic heart failure. Circulation 1995 Sep 15; 92 (6): 1499-506
-
(1995)
Circulation
, vol.92
, Issue.6
, pp. 1499-1506
-
-
Krum, H.1
Sackner-Bernstein, J.D.2
Goldsmith, R.L.3
-
25
-
-
0028947523
-
Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomised study
-
Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomised study. J Am Coll Cardiol 1995; 25 (6): 1225-31
-
(1995)
J Am Coll Cardiol
, vol.25
, Issue.6
, pp. 1225-1231
-
-
Olsen, S.L.1
Gilbert, E.M.2
Renlund, D.G.3
-
26
-
-
10544223267
-
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
-
Dec 1;
-
Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996 Dec 1; 94 (11): 2807-16
-
(1996)
Circulation
, vol.94
, Issue.11
, pp. 2807-2816
-
-
Bristow, M.R.1
Gilbert, E.M.2
Abraham, W.T.3
-
27
-
-
0031230455
-
Safety and efficacy of carvedilol in severe heart failure: The U.S. Carvedilol Heart Failure Study Group
-
Sep;
-
Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure: the U.S. Carvedilol Heart Failure Study Group. J Card Fail 1997 Sep; 3 (3): 173-9
-
(1997)
J Card Fail
, vol.3
, Issue.3
, pp. 173-179
-
-
Cohn, J.N.1
Fowler, M.B.2
Bristow, M.R.3
-
28
-
-
10544231452
-
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
-
Dec 1;
-
Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996 Dec 1; 94 (11): 2800-6
-
(1996)
Circulation
, vol.94
, Issue.11
, pp. 2800-2806
-
-
Colucci, W.S.1
Packer, M.2
Bristow, M.R.3
-
29
-
-
10544251442
-
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE trial
-
Dec 1;
-
Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 1996 Dec 1; 94 (11): 2793-9
-
(1996)
Circulation
, vol.94
, Issue.11
, pp. 2793-2799
-
-
Packer, M.1
Colucci, W.S.2
Sackner-Bernstein, J.D.3
-
30
-
-
0035370722
-
Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis
-
Jun;
-
Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001 Jun; 141 (6): 899-907
-
(2001)
Am Heart J
, vol.141
, Issue.6
, pp. 899-907
-
-
Packer, M.1
Antonopoulos, G.V.2
Berlin, J.A.3
-
31
-
-
1342284053
-
Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish doppler-echocardiographic study (SWEDIC)
-
Jun;
-
Bergström A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004 Jun; 6 (4): 453-61
-
(2004)
Eur J Heart Fail
, vol.6
, Issue.4
, pp. 453-461
-
-
Bergström, A.1
Andersson, B.2
Edner, M.3
-
32
-
-
0036895484
-
Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure
-
Dec;
-
Palazzuoli A, Bruni F, Puccetti L, et al. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail 2002 Dec; 4 (6): 765-70
-
(2002)
Eur J Heart Fail
, vol.4
, Issue.6
, pp. 765-770
-
-
Palazzuoli, A.1
Bruni, F.2
Puccetti, L.3
-
33
-
-
0032958134
-
Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction
-
Apr;
-
Senior R, Basu S, Kinsey C, et al. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 1999 Apr; 137 (4): 646-52
-
(1999)
Am Heart J
, vol.137
, Issue.4
, pp. 646-652
-
-
Senior, R.1
Basu, S.2
Kinsey, C.3
-
34
-
-
1642494797
-
Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: The CAPRICORN echo substudy
-
Jan 20;
-
Doughty RN, Whalley GA, Walsh HA, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN echo substudy. Circulation 2004 Jan 20; 109 (2): 201-6
-
(2004)
Circulation
, vol.109
, Issue.2
, pp. 201-206
-
-
Doughty, R.N.1
Whalley, G.A.2
Walsh, H.A.3
-
35
-
-
0034255060
-
Differential effects of β-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol
-
Aug 1;
-
Metra M, Giubbini R, Nodari S, et al. Differential effects of β-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000 Aug 1; 102 (5): 546-51
-
(2000)
Circulation
, vol.102
, Issue.5
, pp. 546-551
-
-
Metra, M.1
Giubbini, R.2
Nodari, S.3
-
36
-
-
0034816963
-
Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol
-
Oct;
-
Khattar RS, Senior R, Soman P, et al. Regression of left ventricular remodeling in chronic heart failure: comparative and combined effects of captopril and carvedilol. Am Heart J 2001 Oct; 142 (4): 704-13
-
(2001)
Am Heart J
, vol.142
, Issue.4
, pp. 704-713
-
-
Khattar, R.S.1
Senior, R.2
Soman, P.3
-
37
-
-
3342943389
-
The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction: The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)
-
Jan;
-
Remme W, Guenter R, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction: the carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther 2004 Jan; 18 (1): 57-66
-
(2004)
Cardiovasc Drugs Ther
, vol.18
, Issue.1
, pp. 57-66
-
-
Remme, W.1
Guenter, R.2
Hildebrandt, P.3
-
39
-
-
0033662177
-
Congestive heart failure induces endothelial cell apoptosis: Protective role of carvedilol
-
Rössig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol 2000; 36 (7): 2081-9
-
(2000)
J Am Coll Cardiol
, vol.36
, Issue.7
, pp. 2081-2089
-
-
Rössig, L.1
Haendeler, J.2
Mallat, Z.3
-
40
-
-
0033979444
-
Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: Modulation of Fas/Fas ligand and caspase-3 pathway
-
Romeo F, Li D, Shi M, et al. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res 2000; 45: 788-94
-
(2000)
Cardiovasc Res
, vol.45
, pp. 788-794
-
-
Romeo, F.1
Li, D.2
Shi, M.3
-
41
-
-
0032498614
-
Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol
-
Yue T-L, Ma X-L, Wang X, et al. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 1998; 82: 166-74
-
(1998)
Circ Res
, vol.82
, pp. 166-174
-
-
Yue, T.-L.1
Ma, X.-L.2
Wang, X.3
-
42
-
-
0028934620
-
Inhibition of human vascular smooth muscle cell proliferation by the novel multiple-action antihypertensive agent carvedilol
-
Patel MK, Chan P, Betteridge LJ, et al. Inhibition of human vascular smooth muscle cell proliferation by the novel multiple-action antihypertensive agent carvedilol. J Cardiovasc Pharmacol 1995; 25 (4): 652-7
-
(1995)
J Cardiovasc Pharmacol
, vol.25
, Issue.4
, pp. 652-657
-
-
Patel, M.K.1
Chan, P.2
Betteridge, L.J.3
-
43
-
-
0027529916
-
Carvedilol inhibits vascular smooth muscle cell proliferation
-
Sung C-P, Arleth AJ, Ohlstein EH, et al. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993; 21 (2): 221-7
-
(1993)
J Cardiovasc Pharmacol
, vol.21
, Issue.2
, pp. 221-227
-
-
Sung, C.-P.1
Arleth, A.J.2
Ohlstein, E.H.3
-
44
-
-
0027163945
-
Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury
-
Jul;
-
Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci U S A 1993 Jul; 90: 6189-93
-
(1993)
Proc Natl Acad Sci U S A
, vol.90
, pp. 6189-6193
-
-
Ohlstein, E.H.1
Douglas, S.A.2
Sung, C.P.3
-
45
-
-
0028032255
-
Acute pretreatment with carvedilol is sufficient for inhibition of neointima formation following rat carotid artery balloon angioplasty
-
Douglas SA, Vickery-Clark LM, Louden C, et al. Acute pretreatment with carvedilol is sufficient for inhibition of neointima formation following rat carotid artery balloon angioplasty. Pharmacol Commun 1994; 5 (1): 65-72
-
(1994)
Pharmacol Commun
, vol.5
, Issue.1
, pp. 65-72
-
-
Douglas, S.A.1
Vickery-Clark, L.M.2
Louden, C.3
-
46
-
-
20944438124
-
Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure
-
Mar;
-
Frantz RP, Olson LJ, Grill D, et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J 2005 Mar; 149 (3): 541-7
-
(2005)
Am Heart J
, vol.149
, Issue.3
, pp. 541-547
-
-
Frantz, R.P.1
Olson, L.J.2
Grill, D.3
-
47
-
-
4344586997
-
Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction
-
Aug 15;
-
Takeda Y, Fukutomi T, Suzuki S, et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol 2004 Aug 15; 94 (4): 448-53
-
(2004)
Am J Cardiol
, vol.94
, Issue.4
, pp. 448-453
-
-
Takeda, Y.1
Fukutomi, T.2
Suzuki, S.3
-
48
-
-
34250638587
-
Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus
-
Jul;
-
Bank AJ, Kelly AS, Thelen AM, et al. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens 2007 Jul; 20 (7): 777-83
-
(2007)
Am J Hypertens
, vol.20
, Issue.7
, pp. 777-783
-
-
Bank, A.J.1
Kelly, A.S.2
Thelen, A.M.3
-
49
-
-
0034828069
-
Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure
-
de Boer RA, Siebelink H-M, Tio RA, et al. Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure. Eur J Heart Fail 2001; 3: 331-3
-
(2001)
Eur J Heart Fail
, vol.3
, pp. 331-333
-
-
de Boer, R.A.1
Siebelink, H.-M.2
Tio, R.A.3
-
50
-
-
49449115419
-
New aspects of endothelial dysfunction in heart failure [abstract no. 1993]
-
Aug;
-
Refsgaard J, Andreasen F, Goetzsche O, et al. New aspects of endothelial dysfunction in heart failure [abstract no. 1993]. Eur Heart J 1999 Aug; 20 Suppl.: 375
-
(1999)
Eur Heart J
, vol.20
, Issue.SUPPL. 375
-
-
Refsgaard, J.1
Andreasen, F.2
Goetzsche, O.3
-
51
-
-
0030943599
-
Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension
-
Jun 15;
-
Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. Ann Intern Med 1997 Jun 15; 126 (12): 955-9
-
(1997)
Ann Intern Med
, vol.126
, Issue.12
, pp. 955-959
-
-
Giugliano, D.1
Acampora, R.2
Marfella, R.3
-
53
-
-
7744237066
-
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial
-
Nov 10;
-
Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004 Nov 10; 292 (18): 2227-36
-
(2004)
JAMA
, vol.292
, Issue.18
, pp. 2227-2236
-
-
Bakris, G.L.1
Fonseca, V.2
Katholi, R.E.3
-
54
-
-
0025371556
-
Effects of carvedilol on renal function
-
Dupont AG. Effects of carvedilol on renal function. Eur J Clin Pharmacol 1990; 38 Suppl. 2: S96-S100
-
(1990)
Eur J Clin Pharmacol
, vol.38
, Issue.SUPPL. 2
-
-
Dupont, A.G.1
-
55
-
-
0001472278
-
Carvedilol improves renal hemodynamics in patients with chronic heart failure [abstract no. 1987]
-
Oct 27;
-
Abraham WT, Tsvetkova T, Lowes BD, et al. Carvedilol improves renal hemodynamics in patients with chronic heart failure [abstract no. 1987]. Circulation 1998 Oct 27; 98 Suppl.: I378-9
-
(1998)
Circulation
, vol.98
, Issue.SUPPL.
-
-
Abraham, W.T.1
Tsvetkova, T.2
Lowes, B.D.3
-
56
-
-
0029074823
-
Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: A multicenter, randomized, open-label, controlled study versus atenolol
-
Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 1995; 12 (4): 212-21
-
(1995)
Adv Ther
, vol.12
, Issue.4
, pp. 212-221
-
-
Marchi, F.1
Ciriello, G.2
-
57
-
-
0029969823
-
Effect of antihypertensive treatment on qualitative estimates of microalbuminuria
-
Agrawal B, Wolf K, Berger A, et al. Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens 1996; 10: 551-5
-
(1996)
J Hum Hypertens
, vol.10
, pp. 551-555
-
-
Agrawal, B.1
Wolf, K.2
Berger, A.3
-
58
-
-
2942618618
-
Tolerability of carvedilol and ACE-inhibition in mild heart failure: Results of CARMEN (carvedilol ACE-inhibitor remodelling mild CHF evaluation)
-
Komajda M, Lutiger B, Madeira H, et al. Tolerability of carvedilol and ACE-inhibition in mild heart failure: results of CARMEN (carvedilol ACE-inhibitor remodelling mild CHF evaluation). Eur Heart J 2004; 6: 467-75
-
(2004)
Eur Heart J
, vol.6
, pp. 467-475
-
-
Komajda, M.1
Lutiger, B.2
Madeira, H.3
-
59
-
-
30444451911
-
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes
-
Dec;
-
Bakris GL, Fonseca V, Katholi RE, et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005 Dec; 46 (6): 1309-15
-
(2005)
Hypertension
, vol.46
, Issue.6
, pp. 1309-1315
-
-
Bakris, G.L.1
Fonseca, V.2
Katholi, R.E.3
-
60
-
-
0029035966
-
Stereoselective disposition of carvedilol is determined by CYP2D6
-
May;
-
Zhou H-H WA. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 1995 May; 57 (5): 518-24
-
(1995)
Clin Pharmacol Ther
, vol.57
, Issue.5
, pp. 518-524
-
-
Zhou, H.-H.W.1
-
61
-
-
0042233484
-
Carvedilol: A review of its use in chronic heart failure
-
Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs 2003; 63 (16): 1697-741
-
(2003)
Drugs
, vol.63
, Issue.16
, pp. 1697-1741
-
-
Keating, G.M.1
Jarvis, B.2
-
62
-
-
0027506396
-
Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy
-
McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993; 45 (2): 232-58
-
(1993)
Drugs
, vol.45
, Issue.2
, pp. 232-258
-
-
McTavish, D.1
Campoli-Richards, D.2
Sorkin, E.M.3
-
63
-
-
0030843847
-
Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders
-
Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1997; 54 (1): 161-85
-
(1997)
Drugs
, vol.54
, Issue.1
, pp. 161-185
-
-
Dunn, C.J.1
Lea, A.P.2
Wagstaff, A.J.3
-
64
-
-
33947111435
-
Antioxidant activity of carvedilol in cardiovascular disease
-
Apr;
-
Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens 2007 Apr; 25 (4): 731-41
-
(2007)
J Hypertens
, vol.25
, Issue.4
, pp. 731-741
-
-
Dandona, P.1
Ghanim, H.2
Brooks, D.P.3
-
65
-
-
33845574557
-
Profile of carvedilol controlled-release: A new once-daily formulation of carvedilol
-
Dec;
-
Fonarow GC. Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. Expert Opin Pharmacother 2006 Dec; 7 (18): 2533-46
-
(2006)
Expert Opin Pharmacother
, vol.7
, Issue.18
, pp. 2533-2546
-
-
Fonarow, G.C.1
-
66
-
-
33845394025
-
-
Carreira RS, Monteiro P, Gonçalves LM, et al. Carvedilol: just another beta-blocker or a powerful cardioprotector? Cardiovasc Hematol Disord Drug Targets 2006 Dec; 6 (4): 257-66
-
Carreira RS, Monteiro P, Gonçalves LM, et al. Carvedilol: just another beta-blocker or a powerful cardioprotector? Cardiovasc Hematol Disord Drug Targets 2006 Dec; 6 (4): 257-66
-
-
-
-
67
-
-
8444235096
-
Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo
-
Jun 29;
-
Kindermann M, Maack C, Schaller S, et al. Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation 2004 Jun 29; 109 (25): 3182-90
-
(2004)
Circulation
, vol.109
, Issue.25
, pp. 3182-3190
-
-
Kindermann, M.1
Maack, C.2
Schaller, S.3
-
68
-
-
33749118663
-
Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction
-
Oct 2;
-
Packer M, Lukas MA, Tenero DM, et al. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Am J Cardiol 2006 Oct 2; 98 (7 Suppl. 1): 39L-45L
-
(2006)
Am J Cardiol
, vol.98
, Issue.7 SUPPL. 1
-
-
Packer, M.1
Lukas, M.A.2
Tenero, D.M.3
-
69
-
-
33749129554
-
Pharmacokinetic properties of a new controlled-release formulation of carvedilol
-
Oct 2;
-
Tenero DM, Henderson LS, Baidoo CA, et al. Pharmacokinetic properties of a new controlled-release formulation of carvedilol. Am J Cardiol 2006 Oct 2; 98 (7 Suppl. 1): 5L-16L
-
(2006)
Am J Cardiol
, vol.98
, Issue.7 SUPPL. 1
-
-
Tenero, D.M.1
Henderson, L.S.2
Baidoo, C.A.3
-
71
-
-
49449095950
-
-
Data on file. GlaxoSmithKline, 2008
-
Data on file. GlaxoSmithKline, 2008
-
-
-
-
72
-
-
0032957957
-
The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency
-
Jun;
-
Gehr T, Tenero DM, Boyle DA, et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 1999 Jun; 55 (4): 269-77
-
(1999)
Eur J Clin Pharmacol
, vol.55
, Issue.4
, pp. 269-277
-
-
Gehr, T.1
Tenero, D.M.2
Boyle, D.A.3
-
73
-
-
35448958493
-
Ethanol does not alter the pharmacokinetic profile of the controlled-release formulation of carvedilol
-
Nov;
-
Henderson LS, Tenero DM, Campanile AM, et al. Ethanol does not alter the pharmacokinetic profile of the controlled-release formulation of carvedilol. J Clin Pharmacol 2007 Nov; 47 (11): 1358-65
-
(2007)
J Clin Pharmacol
, vol.47
, Issue.11
, pp. 1358-1365
-
-
Henderson, L.S.1
Tenero, D.M.2
Campanile, A.M.3
-
74
-
-
0035978763
-
Effect of carvedilol on survival in severe chronic heart failure
-
May 31;
-
Packer M, Coats A, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001 May 31; 344 (22): 1651-8
-
(2001)
N Engl J Med
, vol.344
, Issue.22
, pp. 1651-1658
-
-
Packer, M.1
Coats, A.2
Fowler, M.B.3
-
75
-
-
3142776467
-
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial
-
Jul 5;
-
Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003 Jul 5; 362 (9377): 7-13
-
(2003)
Lancet
, vol.362
, Issue.9377
, pp. 7-13
-
-
Poole-Wilson, P.A.1
Swedberg, K.2
Cleland, J.G.F.3
-
76
-
-
33749126575
-
Controlled-release carvedilol in the treatment of essential hypertension
-
Oct 2;
-
Weber MA, Sica DA, Tarka EA, et al. Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol 2006 Oct 2; 98 (7 Suppl. 1): 32L-8L
-
(2006)
Am J Cardiol
, vol.98
, Issue.7 SUPPL. 1
-
-
Weber, M.A.1
Sica, D.A.2
Tarka, E.A.3
-
77
-
-
33749340025
-
Cardiovascular risk factors in hypertension: Rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile
-
Oct 2;
-
Bakris GL, Tarka EA, Waterhouse B, et al. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. Am J Cardiol 2006 Oct 2; 98 (7 Suppl. 1): 46L-52L
-
(2006)
Am J Cardiol
, vol.98
, Issue.7 SUPPL. 1
-
-
Bakris, G.L.1
Tarka, E.A.2
Waterhouse, B.3
-
78
-
-
49449088869
-
Compliance with once daily controlled release vs twice daily immediate release carvedilol in patients with heart failure: The CASPER trial
-
Aug;
-
Udelson JE, Pressler SJ, Sackner-Bernstein J, et al. Compliance with once daily controlled release vs twice daily immediate release carvedilol in patients with heart failure: the CASPER trial. J Card Fail 2007 Aug; 13 (6 Suppl. S2): S135
-
(2007)
J Card Fail
, vol.13
, Issue.6 SUPPL. S2
-
-
Udelson, J.E.1
Pressler, S.J.2
Sackner-Bernstein, J.3
-
79
-
-
0035810547
-
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial
-
The CAPRICORN Investigators, May 5;
-
The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001 May 5; 357 (9266): 1385-90
-
(2001)
Lancet
, vol.357
, Issue.9266
, pp. 1385-1390
-
-
|